Allodepleted T-cell immunotherapeutic ATIR101

Drug Overview

Immunotherapy / Targeted Therapy

Allodepleted T-cell immunotherapeutic ATIR101 is a cutting-edge, experimental cellular treatment. In the world of cancer care, it is classified as an Immunotherapy. This is not a chemical drug like chemotherapy; rather, it is a “living medicine” made from human immune cells. It is designed to make stem cell transplants safer and more effective for patients with blood cancers.

Currently, ATIR101 is an investigational therapy. This means it is being tested in advanced clinical trials and is not yet available for general prescription at most hospitals. It has received special “Orphan Drug” and “Regenerative Medicine Advanced Therapy” (RMAT) designations from the US FDA because of its potential to save lives in patients with high-risk leukemia and lymphoma.

• Generic Name: Allodepleted T-cell immunotherapeutic ATIR101 (also known as Tabelecleucel in some research contexts, though ATIR101 is the specific Kiadis/Sanofi formulation).
• US Brand Names: None (Currently investigational).
• Drug Class: Cellular Immunotherapy / T-cell Therapy.
• Route of Administration: Intravenous (IV) Infusion.
• FDA Approval Status: Not FDA Approved; currently in Phase II and Phase III clinical trials.

What Is It and How Does It Work? (Mechanism of Action)

To understand how ATIR101 works, we must first look at the challenge of stem cell transplants. When a patient with leukemia receives a transplant from a “half-matched” donor (like a family member), the donor’s immune cells often see the patient’s body as an enemy. This leads to a deadly condition called Graft-versus-Host Disease (GvHD).

ATIR101 is a Targeted Therapy that solves this problem using a process called “photodynamic depletion.”

1. Selection: Doctors take T-cells (immune soldiers) from the donor.
2. Identification: In a lab, these donor cells are mixed with the patient’s cells. The “bad” donor cells that want to attack the patient’s body become active.
3. Targeting: A special light-sensitive chemical called TH9402 is added. This chemical only enters the active, “bad” cells.
4. Elimination: The cells are exposed to a specific kind of light. This light activates the chemical, which destroys the “bad” cells while leaving the “good” cells alive.
5. Protection: The remaining “good” cells are given to the patient.

At the molecular level, these “good” cells still have their receptors ready to fight infections and kill any remaining cancer cells (the Graft-versus-Leukemia effect). Because the cells that cause GvHD have been removed, the patient gets the protection of a new immune system without the high risk of the new system attacking their own organs.

FDA Approved Clinical Indications

Important Note: ATIR101 is an investigational product and does not yet have official FDA approval for commercial use. It is currently being used in clinical trials for the following:

Oncological Uses (Investigational):

• Haploidentical Stem Cell Transplant Support: Used as an add-on treatment for patients with Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndromes (MDS) who are receiving a transplant from a partially matched donor.
• Immune Reconstitution: To help the body build a new immune system quickly after a transplant.

Non-oncological Uses:

• None at this time.

Dosage and Administration Protocols

The administration of ATIR101 is a highly controlled process that happens weeks after a patient has received their initial stem cell transplant.

Dose Adjustments:

• Renal/Hepatic Insufficiency: Because this is a cell-based therapy and not a chemical processed by the liver or kidneys, standard dose adjustments for organ failure are not usually required. However, the patient must be stable and free of active, severe infections before the cells are infused.

Clinical Efficacy and Research Results

Recent clinical data (2020–2025) has shown that ATIR101 can significantly improve the outcomes of “half-matched” transplants.

• Survival Rates: In Phase II studies (such as the STRIVE trial), patients receiving ATIR101 showed an overall survival rate of approximately 70% to 80% at one year. This is significantly higher than historical rates for patients who did not receive this type of T-cell support.
• GvHD Prevention: Research indicates a major reduction in severe Graft-versus-Host Disease. While traditional transplants often see high rates of severe GvHD, patients using ATIR101 in trials experienced severe (Grade III-IV) GvHD at rates below 5%.
• Disease Progression: By providing “good” T-cells early, the therapy reduces the time a patient is “immune-defenseless,” leading to lower rates of infection-related deaths and a lower chance of the cancer returning (relapse).

Safety Profile and Side Effects

Because ATIR101 involves the immune system, the side effects are usually related to how the new cells interact with the body.

Black Box Warning

There is no Black Box Warning for ATIR101 as it is still in the investigational phase.

Common Side Effects (>10%)

• Fever and Chills: Often occurring shortly after the infusion.
• Nausea: Mild stomach upset during or after the procedure.
• Fatigue: Feeling very tired as the body adjusts to the new cells.
• Mild Rash: A temporary skin reaction as the immune cells begin to work.

Serious Adverse Events

• Graft-versus-Host Disease (GvHD): Although the drug is designed to prevent this, a small number of patients may still develop it.
• Infusion Reactions: Rare but serious allergic-type reactions during the IV drip.
• Infections: While waiting for the cells to fully grow, patients remain at risk for viral or fungal infections.

Management Strategies

• For Infusion Reactions: Patients are often given “pre-meds” like acetaminophen or antihistamines to prevent fevers and chills.
• For GvHD: If symptoms like diarrhea or a severe skin rash appear, doctors use steroids or other immune-calming drugs.
• Monitoring: Patients stay in or near the hospital for several weeks after the infusion so their blood counts and symptoms can be checked daily.

Connection to Stem Cell and Regenerative Medicine

ATIR101 is a landmark therapy in Regenerative Medicine. It acts as a bridge that allows a patient’s body to regenerate a fully functioning immune system. In a standard transplant, it can take 6 to 12 months for a patient to have enough T-cells to stay safe. ATIR101 provides those cells “instantly” after the transplant. By using cellular engineering to weed out harmful cells and keep helpful ones, ATIR101 represents the future of regenerative immunology—helping the body rebuild its defenses without the risk of self-destruction.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

• Donor Screening: The family member donor must undergo a full physical and blood screening to ensure their T-cells are healthy.
• Infection Screen: The patient must be tested for viruses like CMV or EBV, as these can reactivate during the transplant process.
• Chimerism Testing: A blood test to see how much of the donor’s initial transplant has already “taken” in the patient’s bone marrow.

Precautions During Treatment

• Isolation: Patients may need to stay in a “clean room” or avoid crowds for a time after infusion to prevent catching a cold or flu.
• No Live Vaccines: Patients should not receive live vaccines (like the flu nasal spray) during this time.

“Do’s and Don’ts”

• DO report any skin redness, yellowing of the eyes, or watery diarrhea to your doctor immediately.
• DO keep all follow-up appointments for blood work.
• DON’T take any new herbal supplements or over-the-counter drugs without asking your transplant team.
• DON’T worry if you feel a “flu-like” sensation right after the infusion; this is often a sign the cells are waking up.

Legal Disclaimer

This guide is for informational purposes only and does not constitute medical advice. ATIR101 is an investigational therapy and is not currently FDA-approved for general use. It should only be administered by qualified oncology and transplant specialists within a clinical trial. Always consult your healthcare provider regarding any questions about a medical condition or treatment. The field of immunotherapy is rapidly evolving; ensure you discuss the most current trial data with your medical team.